Try our beta test site
126 studies found for:    anti-EGFR antibodies
Show Display Options
Rank Status Study
1 Recruiting Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Biological: Recombinant Anti-EGFr Antibody
2 Recruiting Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer
Condition: Breast Cancer
Intervention: Drug: anti-EGFR-IL-dox
3 Completed Anti-EGFR Immunoliposomes in Solid Tumors
Condition: Solid Tumors
Intervention: Drug: anti-EGFR immunoliposomes loaded with doxorubicin
4 Recruiting Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer
Conditions: Neoplasm Metastasis;   Gastric Cancer;   Colorectal Cancer
Intervention: Biological: GC1118
5 Active, not recruiting BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Condition: Cancer
Interventions: Drug: Dabrafenib;   Drug: Trametinib;   Drug: Panitumumab;   Drug: 5-fluorouracil
6 Enrolling by invitation Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Biological: Recombinant full human Anti-EGFR Monoclonal Antibody
7 Completed Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Patients With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFr Therapy
Condition: Colorectal Cancer
Interventions: Biological: IMC-A12;   Biological: cetuximab
8 Completed PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: Cetuximab
9 Completed
Has Results
Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
Condition: Colorectal Cancer
Intervention: Drug: Everolimus (RAD001)
10 Recruiting In Vivo EGFR-ECD Molecular Imaging Using [68Ga]- Labelling Anti-EGFR Affibody Molecule
Condition: Molecular Imaging
Intervention: Other: 68Ga-NODAGA-Ac-Cys-ZEGFR:1907
11 Completed
Has Results
Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
Condition: Carcinoma, Squamous Cell of Head and Neck
Intervention: Drug: Sym004
12 Recruiting Treatment Optimization of Cetuximab in Patients With Metastatic Colorectal Cancer Based on Tumor Uptake of 89Zr-labeled Cetuximab Assessed by PET
Condition: Colorectal Cancer
Intervention: Behavioral: pharmacodynamic purposes of 89Zr-labelled cetuximab and kinase activity profiles
13 Recruiting ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX -1st Line
Condition: Metastatic Colorectal Cancer
Intervention:
14 Unknown  CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
Condition: Advanced Glioma
Intervention: Biological: anti-EGFR CAR T
15 Withdrawn Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
Condition: Metastatic Colorectal Cancer
Intervention: Drug: Sym004
16 Suspended Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Biological: Aldesleukin;   Biological: Antibody Therapy;   Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Biological: Sargramostim
17 Suspended A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas
Condition: Gliomas
Intervention: Drug: MAb-425
18 Completed Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer
Condition: Stage IV Non-small Cell Lung Cancer
Intervention: Drug: Cetuximab in combination with Carboplatin/Gemcitabine
19 Completed Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: cetuximab;   Drug: irinotecan hydrochloride
20 Completed
Has Results
ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Lung Cancer
Interventions: Drug: Docetaxel;   Drug: Vandetanib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.